Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date: April 20, 2018
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Securities Issued: 6,600,000 shares of Common Stock and 6,600,000 Warrants (50% Class A, 50% Class B).
- Purchase Price: $0.39 per share for Common Stock; $0.39 exercise price for Warrants.
- Gross Proceeds: Approximately $2,574,000 (calculated as 6,600,000 shares x $0.39).
- Net Proceeds: Estimated at $2,393,820 after deducting placement agent fees and transaction expenses.
- Placement Agent Fee: 7% of gross proceeds paid to Maxim Group LLC.
- Expense Reimbursement: Up to $50,000 for legal fees and other expenses.
- Use of Proceeds: Production of Ampligen, operational improvements, working capital, and general corporate purposes.
Material Changes and Transaction Terms
This filing represents a material change in the company's capital structure due to the issuance of new equity. Key terms include:
- Warrant Terms: Warrants are not exercisable for six months post-issuance. Class A Warrants expire two years after becoming exercisable; Class B Warrants expire five years after becoming exercisable.
- Lock-up Period: The Company agreed not to issue or agree to issue Common Stock or equivalents for 60 days following the expected closing date (April 24, 2018).
- Registration Status: Common Shares sold under an effective Form S-3 shelf registration. Warrants sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Outlook, Risks, and Management Commentary
Management Commentary: The transaction is intended to secure funding specifically for the production of the company's product, Ampligen, and to support general operations. The closing is expected on or about April 24, 2018, subject to customary conditions.
Risks and Contingencies:
- Closing Conditions: The transaction is not yet closed and is subject to satisfaction of customary closing conditions.
- Warrant Exercise: Gross proceeds from the warrants will only be realized if and when they are exercised for cash.
- Representations: The filing explicitly states that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as factual statements of the company's condition by stockholders.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $2,393,820 net proceeds receipt.
- Confirm the specific allocation of funds toward Ampligen production versus general working capital.
- Monitor the 60-day lock-up period expiration for potential future dilution.
- Review the attached Press Release (Exhibit 99.1) for additional context on the private placement.
- Check subsequent filings for the exercise status of the Class A and Class B Warrants.